BioSpace News Archive

Elixir Medical announced that the PINNACLE I study evaluating the safety and performance of its LithiX™ Hertz Contact Intravascular Lithotripsy System for treatment of moderate to severely calcified coronary artery lesions met its primary safety and effectiveness endpoint of clinical success.

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended March 31, 2024, as well as key recent clinical and corporate developments.

Know Labs, Inc. today announced the appointment of Chris Somogyi as President, International.

Phenomix Sciences has secured $5.5 million in Series A funding from new investors, DexCom, Inc. and Labcorp, and existing investors, including Health2047.

Traws Pharma, Inc. today announced financial results for the first quarter of 2024, and provided a business update.

XCath, an early-stage medical device company dedicated to expanding endovascular treatment modalities through its smart steerable guidewires and robotic systems, successfully completed a first-of-its-kind live telerobotic trial for stroke treatment between Abu Dhabi and South Korea at Abu Dhabi Global Healthcare Week.

Adolore BioTherapeutics announced the publication of its manuscript titled, " rdHSV-CA8 non-opioid analgesic gene therapy decreases somatosensory neuronal excitability by activating Kv7 voltage-gated potassium channels,[1]” in the peer-reviewed journal, Frontiers in Molecular Neuroscience.

XSeed Labs - a collaboration between BioMed X and Boehringer Ingelheim, announces the start of its first research team on the Boehringer Ingelheim campus in Ridgefield, Connecticut.

Results from the largest prospective study of stroke AI software were presented today at the European Stroke Organisation Conference (ESOC) in Basel

According to latest study, the U.S. cancer biopsy market size was valued at USD 10.21 billion in 2023 and is projected to surpass around USD 29.34 billion by 2033, registering a CAGR of 11.13% over the forecast period of 2024 to 2033.